Keywords: Roche, Genentech, 2009 financial results

Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs

Article | 03 February 2010

Print This

Swiss drug major Roche posted full-year 2009 profits that missed forecasts due to acquisition costs related to US biotech firm Genentech ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in